CurrentCignaPolicy N/A

Parkinson's Disease - Tolcapone Prior Authorization Policy

Defines prior authorization requirements and coverage criteria for tolcapone (Tasmar) for treatment of Parkinson's disease for Cigna-administered health benefit plans; applies to prescribers and reviewers making coverage determinations.

Policy Summary

PayerCigna

PolicyParkinson's Disease - Tolcapone Prior Authorization Policy

Policy CodePolicy N/A

Change TypeRevised prior therapy requirement

Effective DateN/A

Next Review DateMar 12, 2025

Key ActionObtain prior authorization and document prior trial of entacapone or opicapone plus current carbidopa/levodopa and neurologist involvement.

SourceLink

POLICY UPDATE CHANGES

The requirement that the patient has tried an entacapone product was changed to the patient has tried an entacapone product or Ongentys (opicapone capsules).

1 yearinitial approval duration

liver failureboxed warning

requires neurologistspecialist

entacapone or opicaponeprior trial required

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indication

Approve for 1 year if the patient meets ALL of the following (A, B, and C):

A: Patient is currently receiving carbidopa/levodopa therapy
B
- B.i: According to the prescriber, patient had significant intolerance to entacapone or opicapone
- B.ii: According to the prescriber, patient had inadequate efficacy with entacapone or opicapone
C: The medication is prescribed by or in consultation with a neurologist

ref”:

title": "inv-01: COVERAGE CRITERIA — Approve for 1 year if the patient meets ALL of the following (A, B, and C)."

Tolcapone (Tasmar) is considered experimental, investigational, or unproven for any use(s) other than Parkinson's disease. Requests for tolcapone for indications outside the FDA‑approved use for idiopathic Parkinson's disease may be denied.

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required. Approvals provided for 1 year when criteria are met. Tolcapone must be prescribed by or in consultation with a neurologist due to specialized evaluation and monitoring requirements.

Approval duration: 1 year when criteria met
Prescription must be by or in consultation with a neurologist

Documentation Required

Required Clinical Documentation

Documentation must show the patient is currently receiving carbidopa/levodopa therapy and that the prescriber has evaluated response/tolerability to prior COMT inhibitor therapy. Include clinical rationale for tolcapone (e.g., entacapone/opicapone intolerance or inadequate efficacy), relevant treatment history, and specialist consultation note.

Document current carbidopa/levodopa therapy
Document trial and outcome of entacapone product or Ongentys (opicapone) with details of intolerance or inadequate efficacy
Include neurologist prescriber or consultation note

Step Therapy

Required Prior Trial of Alternative COMT Inhibitors

Step therapy requires a prior trial of an entacapone product or Ongentys (opicapone capsules) before tolcapone unless the prescriber documents intolerance or inadequate efficacy.

Required prior trial: entacapone product OR Ongentys (opicapone capsules)
Exception: documented significant intolerance or inadequate efficacy per prescriber

Denial Risk

Non‑approved Uses

Use of tolcapone for any indication other than FDA‑approved Parkinson's disease is considered experimental, investigational, or unproven and is not covered.

Non‑approved uses are not covered (experimental/investigational)

Definitions

inv-08: Tolcapone (Tasmar) — key facts

DrugTolcapone (brand name: Tasmar)

Drug class / mechanismCatechol-O-methyltransferase (COMT) inhibitor

FDA‑approved indicationAdjunct to levodopa/carbidopa for treatment of signs and symptoms of idiopathic Parkinson's disease

Key safety concernBoxed Warning: risk of potentially fatal acute fulminant liver failure; reserve for patients with motor fluctuations not responding satisfactorily to other adjunctive therapies

Typical use contextUsed to reduce motor fluctuations as an adjunct to levodopa/carbidopa when other adjunctive therapies are ineffective or not appropriate

Prescribing considerationUse should be reserved for patients with symptom fluctuations and when other adjunctive therapies are not satisfactory or appropriate